BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/13/2020 3:40:10 AM | Browse: 885 | Download: 2135
 |
Received |
|
2020-08-13 14:54 |
|
Peer-Review Started |
|
2020-08-13 14:55 |
|
First Decision by Editorial Office Director |
|
2020-09-16 18:20 |
|
Return for Revision |
|
2020-09-16 18:20 |
|
Revised |
|
2020-09-29 17:53 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2020-10-16 08:30 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2020-10-19 20:16 |
|
Articles in Press |
|
2020-10-19 20:16 |
|
Edit the Manuscript by Language Editor |
|
2020-10-22 22:41 |
|
Typeset the Manuscript |
|
2020-11-12 01:34 |
|
Publish the Manuscript Online |
|
2020-11-13 03:40 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Endocrinology & Metabolism |
| Manuscript Type |
Observational Study |
| Article Title |
Glucagon-like-1 receptor agonists and sodium/glucose cotransporter 2 inhibitors combination—are we exploiting their full potential in a real life setting
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Maja Cigrovski Berkovic, Ines Bilic-Curcic, Tomislav Bozek, Davorka Herman Mahecic, Sanja Klobucar Majanovic, Silvija Canecki-Varzic, Jelena Andric, Srecko Marusic and Anna Mrzljak |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Anna Mrzljak, MD, PhD, Reader (Associate Professor), Department of Medicine, Merkur University Hospital, School of Medicine, University of Zagreb, Zajčeva 19, Zagreb 10000, Croatia. anna.mrzljak@mef.hr |
| Key Words |
Sodium/glucose cotransporter 2 inhibitors; Glucagon-like-1 receptor agonists; Type 2 diabetes mellitus; Body weight; Glycemic control; Cardiovascular complications |
| Core Tip |
Both glucagon-like-1 receptor agonists and sodium/glucose cotransporter 2 inhibitors when added sequentially to the other or simultaneously decrease the hemoglobin A1c (HbA1c), and reduce the body mass index, but the weight loosing and glucose-lowering potential is not additive in case of their simultaneous use. Half of the patients achieved target HbA1c below 7%, irrespective of treatment group (sequential or simultaneous addition). 5% weight loss was dominantly achieved in the simultaneous therapy group. Composite outcome (reduction of HbA1c below 7% with 5% weight loss) was achieved in 32.3%, while 18.2% of total patients attained composite outcome defined as HbA1c below 7% with 5% weight loss and LDL cholesterol < 2.5 mmol/L. |
| Publish Date |
2020-11-13 03:40 |
| Citation |
Cigrovski Berkovic M, Bilic-Curcic I, Bozek T, Herman Mahecic D, Klobucar Majanovic S, Canecki-Varzic S, Andric J, Marusic S, Mrzljak A. Glucagon-like-1 receptor agonistsGLP-1RA and sodium/glucose cotransporter 2 inhibitors combination—are we exploiting their full potential in a real life setting. World J Diabetes 2020; 11(11): 540-552 |
| URL |
https://www.wjgnet.com/1948-9358/full/v11/i11/540.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v11.i11.540 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
